1.Surfactant replacement therapy in neonatal respiratory distress syndrome.
Chan Ok PARK ; Boung Yul LIM ; Byeong Gie YEO ; Ji Ho SONG ; Eun Kyung SOHN ; Chong Woo BAE ; Sa Jun CHUNG ; Chang Il AHN
Journal of the Korean Pediatric Society 1991;34(9):1211-1222
No abstract available.
Respiratory Distress Syndrome, Newborn*
2.Diagnostic accuracy of stable microbubble rating test for the early detection of neonatal respiratory distress syndrome.
Jung Sam JUN ; Chy Hyung PARK ; Jong Woo BAE ; Chang Il AHN
Journal of the Korean Pediatric Society 1992;35(10):1361-1368
No abstract available.
Microbubbles*
;
Respiratory Distress Syndrome, Newborn*
3.Perinatal Factors Influencing to the Response of Surfactant Replacement Therapy for the Neonatal Respiratory Distress Syndrome Patients.
Hye Jin KWON ; Seung Ah HONG ; Soon Woo KIM ; Yoon Jung CHO ; Sang Lak LEE ; Joon Sik KIM ; Tae Chan KWON
Korean Journal of Perinatology 2001;12(4):459-465
No abstract available.
Humans
;
Respiratory Distress Syndrome, Newborn*
4.The effect of antenatal betamethasone on prevent respiratory distress syndrome in premature infants
Journal Ho Chi Minh Medical 2004;8(1):39-47
A retrospective controlled cohort analysis of live-born singleton neonates prematurely born before 34 weeks’gestation was conducted in Tu Du Maternity Hospital in HCMC from January 2000 to December 2000. 217 premature infants were devided into 2 groups: group 1: 80 infants, whose mother taking prenatal betamethasone and group 2: 137 infants, whose mother without taking prenatal betamethasone. Data were analyzed with the T test, the Chi square test and Fisher exact test. Relative risk, 95% confident interval, other maternal and infant factors were calculated for betamethasone use. The results: the independent variables, which included maternal demographic, maternal clinical risk, infant characteristics were controlled. There were a significant statistical difference for Respiratory distress syndrome incidence of infants between 2 groups. Mean duration of ventilator and mean duration of neonatal hospital care were statistically different. All other short term side effects analyzed were similar between 2 groups
Respiratory Distress Syndrome, Newborn
;
Betamethasone
;
Infant, Premature
5.External laryngocoele: A rare cause of stridor in neonate
Nor Idayu M YUSOF ; Mohamamad Tamim JAMIL ; Irfan MOHAMAD
Brunei International Medical Journal 2012;8(1):43-47
A laryngocoele is an abnormal dilatation of the laryngeal saccule. It is a rare cause of stridor in the newborn or in early infancy. Most laryngocoeles are asymptomatic but symptoms of hoarseness, feeding difficulty, lump in the neck and upper airway obstruction may occur. We report a case of external laryngocoele causing partial airway obstruction in early infancy. Spontaneous resolution occurred following conservative medical management thus avoiding surgical intervention.
Infant
;
Complications
;
Respiratory Distress Syndrome, Newborn
6.The first evaluation of clinical efficacy of high-frequency oscillatory ventilation in the treatment of seriously respiratory distress syndrome in preterm babies at Tu Du hospital.
Xuan Minh Ngo ; Dung Van Nguyen
Journal of Medical Research 2007;55(6):65-71
Background:Pulmonary disease is still the main reason cause diseases and mortality for preterm babies. Objectives:This study aims to evaluate of the clinical efficacy of high-frequency oscillatory ventilation in the treatment of preterm infants who have seriously respiratory distress syndrome required mechanical ventilation. Subjects and method:A prospective clinical trail was conducted at Neonatal Unit of Tu Du Hospital from 1st December 2005 to 30th November 2006. Intervention: Patients were randomized to high-frequency oscillatory ventilation (20 patients) or conventional mechanical ventilation-CMV (59 patients). High-frequency oscillatory ventilation(HFOV) was used in high lung volume strategy. Results:The two groups of patients were similar in demographic distribution of birth weight, gestational age, gender, surfactant after birth. Patients on HFOV were ventilator \ufffd?dependent (2.14 \xb1 1.76 vs 3.48 \xb1 2.70 day. p=0.004) and respiratory pressure support (4.01 \xb1 2.23 vs 6.55 \xb1 day. p =0.02) for a shorter time than patients on CMV. Conclusion: First intention HFOV with high volume strategy shortened the time of ventilation and pressure support in preterm infants with seriously respiratory distress syndrome. In the future, it will be necessary to have the tremendous research for the efficacy of HFOV in order to decrease the ratio of bronchopulmonary dysplasia of infants who have seriously respiratory distress syndrome required mechanical ventilation.
Respiratory Distress Syndrome
;
Newborn/ therapy
;
Infant
;
Premature
7.Surfactant replacement therapy for prevention and treatment of respiratory distress syndrome of preterm infants
Ho Chi Minh city Medical Association 2005;10(3):132-134
During the period between 1999 and 2005, a clinical trial has been conducted at Hung Vuong Hospital to assess the efficacy of surfactant replacement therapy for prevention and treatment of respiratory distress syndrome (RDS) in preterm infants. Results: A total of 83 preterm infants with gestational age from 27 to 33 weeks were recruited, of whom 45 assigned to the prophylactic group and 38 to the rescue group. Percentages of developing or not reassuring RDS were 5.4% and 21.1% in the prophylactic and the rescue group, respectively (p<0.001). However, the difference in neonatal mortality was not statistically significant: 8.9% in the prophylactic in comparison with 15.8% in the rescue group
Respiratory Distress Syndrome, Adult
;
Respiratory Distress Syndrome
;
Newborn
;
Therapeutics
;
Pulmonary Surfactants
;
Prevention & control
;
Therapeutics
9.Changes of neonatal mortality rate between 'pre' and 'post' surfactant period.
Young Youn CHOI ; Ji Young PARK ; Chang Yee CHO ; Jae Sook MA ; Tai Ju HWANG
Journal of Korean Medical Science 1999;14(1):45-51
The objective of this study was to determine how the neonatal mortality rate has changed since surfactant (S) therapy was introduced in our Neonatal Intensive Care Unit (NICU), and to evaluate the efficacy of surfactant therapy in respiratory distress syndrome (RDS) patients. Incidences of risk babies such as outborns, prematurity, low birth weight infants and RDS, and neonatal mortality rates were compared between 'pre' (control, 1988 to 1991, n=4,861) and 'post' S period (study, 1993 to 1996, n=5,430). In RDS patients of 'post' S period, neonatal mortality rate was compared between S-treated and non-treated patients, and chest X-ray and ventilatory parameters were compared between pre- and post-72 hr of surfactant treatment. Surfactant therapy showed short term effects, judging by the decrease of early neonatal deaths and improvement of chest X-ray and ventilatory parameters in RDS patients. The overall neonatal mortality rate had a tendency to decrease in spite of increased incidences of risk babies in 'post' S period but it was less than expected. The reasons were thought to be that we had a high proportion of risk babies, and there was some bias in patient selection for surfactant therapy and its use. In conclusion, with the active prevention of risk baby delivery and appropriate use of surfactant, better results could be expected.
Female
;
Human
;
Incidence
;
Infant Mortality
;
Infant, Newborn
;
Male
;
Pulmonary Surfactants/therapeutic use*
;
Respiratory Distress Syndrome/mortality*
;
Respiratory Distress Syndrome/epidemiology
;
Respiratory Distress Syndrome/drug therapy*
;
Risk Factors
10.Report of a case with Potter's syndrome.
Chinese Journal of Pediatrics 2004;42(7):556-556